Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Aeglea Bio Therapeutics stock price, quote, forecast and news

AGLE
US00773J1034
A2AG5H

Price

39.76
Today +/-
+0
Today %
+0 %
P

Aeglea Bio Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Aeglea Bio Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aeglea Bio Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aeglea Bio Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aeglea Bio Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aeglea Bio Therapeutics Stock Price History

DateAeglea Bio Therapeutics Price
3/20/202439.76 undefined
3/19/202438.39 undefined

Aeglea Bio Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aeglea Bio Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aeglea Bio Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aeglea Bio Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aeglea Bio Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aeglea Bio Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aeglea Bio Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aeglea Bio Therapeutics’s growth potential.

Aeglea Bio Therapeutics Revenue, EBIT and net profit per share

DateAeglea Bio Therapeutics RevenueAeglea Bio Therapeutics EBITAeglea Bio Therapeutics Net Income
2028e0 undefined-357 M undefined-25.39 M undefined
2027e0 undefined-306 M undefined-22.5 M undefined
2026e0 undefined-255 M undefined-19.4 M undefined
2025e0 undefined-34.91 M undefined-16.1 M undefined
2024e13.6 M undefined-73.95 M undefined-9.55 M undefined
2023e1.29 M undefined-224.5 M undefined-21.96 M undefined
20222.33 M undefined-84.78 M undefined-83.82 M undefined
202118.74 M undefined-65.65 M undefined-65.8 M undefined
20200 undefined-81.48 M undefined-80.89 M undefined
20190 undefined-80.33 M undefined-78.25 M undefined
20183.89 M undefined-45.46 M undefined-44.35 M undefined
20175.21 M undefined-27.68 M undefined-27.24 M undefined
20164.63 M undefined-21.91 M undefined-21.7 M undefined
20156.09 M undefined-11.32 M undefined-11.52 M undefined
20140 undefined-8.9 M undefined-10.35 M undefined
20130 undefined-1.89 M undefined-1.94 M undefined

Aeglea Bio Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e
006453001821130000
----33.3325.00-40.00----88.89-50.001,200.00----
----------------
0000000000000000
-1-8-11-21-27-45-80-81-65-84-224-73-34-255-306-357
---183.33-525.00-540.00-1,500.00---361.11-4,200.00-22,400.00-561.54----
-1-10-11-21-27-44-78-80-65-83-21-9-16-19-22-25
-900.0010.0090.9128.5762.9677.272.56-18.7527.69-74.70-57.1477.7818.7515.7913.64
0.460.460.460.390.610.831.282.132.633.37000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Aeglea Bio Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aeglea Bio Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2013201420152016201720182019202020212022
                   
4.62.633.163.550.374.571.9146.393.155.7
001.71.23.100000
0000000000
0000000000
00.13.51.71.62.22.63.54.96.2
4.62.738.366.45576.774.5149.89861.9
00.20.30.60.917.29.99.27.2
0000000000
0000000000
0000000000
0000000000
00000.20.11.51.91.91.6
00.20.30.61.11.18.711.811.18.8
4.62.938.66756.177.883.2161.6109.170.7
                   
5.214.158.30000000
001.4108.2123184.3255.1415.8425.8476
-1.9-12.3-23.6-45.3-72.5-116.9-195.1-276-341.8-425.6
0000-1000100000
0000000000
3.31.836.162.950.467.460.1139.88450.4
0.20.30.20.20.40.73.22.33.30.7
0.20.72.33.75.29.615.214.21413.4
1000.100002.40.5
0000000000
000000004000
1.412.545.610.318.416.520.114.6
0000000000
0000000000
0000.10.10.14.75.35.86.2
0000.10.10.14.75.35.86.2
1.412.54.15.710.423.121.825.920.8
4.72.838.66756.177.883.2161.6109.971.2
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aeglea Bio Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aeglea Bio Therapeutics's financial health and stability.

Assets

Aeglea Bio Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aeglea Bio Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aeglea Bio Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aeglea Bio Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2013201420152016201720182019202020212022
-1-10-11-21-27-44-78-80-65-83
00000001,0001,0001,000
0000000000
00-11077-21-5
0211245687
0000000000
0000000000
0-7-10-18-24-32-65-75-53-80
000000-1-400
00-4-12-22-15-1-7-2257
00-3-11-21-140-3-2257
0000000000
0000000000
4543005765154143
454149125765154142
00-2491100000
0000000000
4-12618-349-171-7419
-0.3-7.52-11.19-19.05-25.24-32.61-67.18-80.06-54.29-80.18
0000000000

Aeglea Bio Therapeutics stock margins

The Aeglea Bio Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aeglea Bio Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aeglea Bio Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aeglea Bio Therapeutics's sales revenue. A higher gross margin percentage indicates that the Aeglea Bio Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aeglea Bio Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aeglea Bio Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aeglea Bio Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aeglea Bio Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aeglea Bio Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aeglea Bio Therapeutics Margin History

Aeglea Bio Therapeutics Gross marginAeglea Bio Therapeutics Profit marginAeglea Bio Therapeutics EBIT marginAeglea Bio Therapeutics Profit margin
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %-543.75 %-70.23 %
2023e0 %-17,376.32 %-1,700.04 %
20220 %-3,638.63 %-3,597.42 %
20210 %-350.32 %-351.12 %
20200 %0 %0 %
20190 %0 %0 %
20180 %-1,168.64 %-1,140.1 %
20170 %-531.29 %-522.84 %
20160 %-473.22 %-468.68 %
20150 %-185.88 %-189.16 %
20140 %0 %0 %
20130 %0 %0 %

Aeglea Bio Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Aeglea Bio Therapeutics earnings per share therefore indicates how much revenue Aeglea Bio Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aeglea Bio Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aeglea Bio Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aeglea Bio Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aeglea Bio Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aeglea Bio Therapeutics Revenue, EBIT and net profit per share

DateAeglea Bio Therapeutics Sales per ShareAeglea Bio Therapeutics EBIT per shareAeglea Bio Therapeutics Earnings per Share
2028e0 undefined0 undefined-6.27 undefined
2027e0 undefined0 undefined-5.56 undefined
2026e0 undefined0 undefined-4.79 undefined
2025e0 undefined0 undefined-3.98 undefined
2024e3.36 undefined0 undefined-2.36 undefined
2023e0.32 undefined0 undefined-5.43 undefined
20220.69 undefined-25.16 undefined-24.87 undefined
20217.13 undefined-24.96 undefined-25.02 undefined
20200 undefined-38.25 undefined-37.98 undefined
20190 undefined-62.76 undefined-61.13 undefined
20184.69 undefined-54.77 undefined-53.43 undefined
20178.54 undefined-45.38 undefined-44.66 undefined
201611.87 undefined-56.18 undefined-55.64 undefined
201513.24 undefined-24.61 undefined-25.04 undefined
20140 undefined-19.35 undefined-22.5 undefined
20130 undefined-4.11 undefined-4.22 undefined

Aeglea Bio Therapeutics business model

Aeglea Bio Therapeutics Inc is a biotechnology company that aims to develop innovative treatments for rare genetic diseases and cancer. The company was founded in 2013 in Austin, Texas, and is listed on the NASDAQ stock exchange since March 2017. Aeglea Bio Therapeutics specializes in the development and commercialization of therapeutics for rare genetic diseases and cancer. They have a pipeline of products in clinical development focusing on various indications, including arginemia, ASS1-negative cancer, and metastatic breast cancer. Their first therapeutic application, Pegzilarginase, was approved by the FDA in January 2021 for the treatment of arginemia. They also have other products in clinical development, such as AEB1102 for ASS1-negative cancer and AEB3103 for metastatic breast cancer. Aeglea Bio Therapeutics works with patient organizations to advance research and development of therapies and improve patient access to new treatment options. Overall, Aeglea Bio Therapeutics has the potential to become a significant player in the biotechnology industry. Aeglea Bio Therapeutics is one of the most popular companies on Eulerpool.com.

Aeglea Bio Therapeutics SWOT Analysis

Strengths

Aeglea Bio Therapeutics Inc possesses advanced expertise in biotechnology, allowing the company to develop innovative and specialized solutions. This expertise provides a competitive advantage in the market and positions the company as a leader in the field.

The company has a diverse product pipeline with multiple drug candidates targeting different diseases and therapeutic areas. This diversity mitigates the risk associated with relying on a single product, and provides potential for revenue growth from various sources.

Weaknesses

Aeglea Bio Therapeutics Inc heavily relies on the success of its clinical trials to bring its drug candidates to market. Any delays or failures in these trials could negatively impact the company's financial performance and reputation, highlighting a vulnerability.

Opportunities

The increasing demand for targeted therapies presents a significant opportunity for Aeglea Bio Therapeutics Inc. Its specialized drug candidates have the potential to address unmet medical needs and attract a substantial market share in the healthcare industry.

Forming strategic collaborations with other pharmaceutical companies or research institutions can provide Aeglea Bio Therapeutics Inc with access to additional resources, expertise, and funding. Such collaborations can enhance the company's research capabilities and accelerate the development of its drug candidates.

Threats

Aeglea Bio Therapeutics Inc operates in a highly regulated industry, making it susceptible to regulatory challenges. Adhering to strict regulations and obtaining necessary approvals can be time-consuming and expensive, potentially affecting the company's ability to bring its products to market in a timely manner.

The biotechnology sector is fiercely competitive, with numerous established players and new entrants constantly emerging. Aeglea Bio Therapeutics Inc faces competition from both large pharmaceutical companies and smaller biotech startups, which may impact its market share and pricing power.

Aeglea Bio Therapeutics Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Aeglea Bio Therapeutics Revenue by Segment

Segmente202320222021
License--12 M USD
Development fee member--6.74 M USD
Development Fee-2.33 M USD-
Development fee and royalty886,000 USD--

Aeglea Bio Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aeglea Bio Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Aeglea Bio Therapeutics shares outstanding

The number of shares was Aeglea Bio Therapeutics in 2023 — This indicates how many shares 3.37 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aeglea Bio Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aeglea Bio Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aeglea Bio Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aeglea Bio Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aeglea Bio Therapeutics Stock splits

In Aeglea Bio Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Aeglea Bio Therapeutics.

Aeglea Bio Therapeutics list of shareholders

%
Name
Stocks
Change
Date
9.34902 % Fairmount Funds Management LLC378,422378,4226/30/2023
8.71520 % Wellington Management Company, LLP352,767352,7676/30/2023
6.27514 % Logos Global Management LLC254,000128,2857/6/2023
6.26844 % VR Adviser, LLC253,729253,7296/30/2023
4.94105 % EcoR1 Capital, LLC200,000200,0006/30/2023
4.84223 % Affinity Asset Advisors LLC196,000196,0006/30/2023
4.58861 % Driehaus Capital Management, LLC185,734185,7346/30/2023
4.05285 % Nantahala Capital Management, LLC164,048-18,2726/30/2023
4.01204 % Suvretta Capital Management, LLC162,39606/30/2023
3.88979 % Polar Capital LLP157,448157,4487/19/2023
1
2
3
4
5
...
10

Most common questions regarding Aeglea Bio Therapeutics

What values and corporate philosophy does Aeglea Bio Therapeutics represent?

Aeglea Bio Therapeutics Inc represents a commitment to innovation, scientific excellence, and improving patients' lives. With a focus on developing transformative therapies, Aeglea Bio Therapeutics is dedicated to addressing unmet medical needs in the field of rare genetic diseases. The company's corporate philosophy revolves around leveraging their expertise in human enzyme biology to develop novel therapeutic solutions. Aeglea Bio Therapeutics believes in fostering strong collaborations, utilizing cutting-edge technologies, and advancing patient-centric approaches. By combining their passion for scientific discovery with a patient-driven mindset, Aeglea Bio Therapeutics strives to make a meaningful impact in the lives of individuals affected by rare diseases.

In which countries and regions is Aeglea Bio Therapeutics primarily present?

Aeglea Bio Therapeutics Inc is primarily present in the United States of America.

What significant milestones has the company Aeglea Bio Therapeutics achieved?

Aeglea Bio Therapeutics Inc has achieved significant milestones since its inception. Notably, the company successfully completed a Phase 1 clinical trial for its lead product candidate, AEB1102, demonstrating its safety and tolerability. Aeglea also received Fast Track Designation from the FDA for AEB1102 in combination with pembrolizumab for the treatment of cancer. In addition, the company expanded its pipeline by initiating a Phase 1/2 trial for AEB3103 in patients with Arginase 1 Deficiency, a rare genetic disorder. These achievements highlight Aeglea Bio Therapeutics Inc's commitment to developing innovative therapies and addressing unmet medical needs.

What is the history and background of the company Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics Inc, a leading biotechnology company, was founded in 2013 and is headquartered in Austin, Texas. The company focuses on developing innovative therapeutics to improve the lives of patients with rare genetic diseases and cancer. Aeglea Bio Therapeutics utilizes its proprietary technology platform, known as Aeglea's Engineered Human Enzyme Products (HEPs), to design and manufacture therapeutic enzymes. These enzymes are developed to target and degrade specific amino acids in the body, addressing the underlying metabolic imbalances associated with certain diseases. With a strong research and development pipeline, Aeglea Bio Therapeutics aims to provide patients with breakthrough treatments that have the potential to transform their lives.

Who are the main competitors of Aeglea Bio Therapeutics in the market?

The main competitors of Aeglea Bio Therapeutics Inc in the market include companies such as Amgen, Incyte Corporation, and bluebird bio. These companies operate in the biopharmaceutical industry and also focus on the development of innovative therapies and treatments. Aeglea Bio Therapeutics Inc, based in the United States, is known for its research in the field of human biochemistry and genetic insights to develop transformative medicines. As it continues to strive for advancements in the industry, it faces competition from these industry leaders in delivering cutting-edge solutions for various diseases and medical conditions.

In which industries is Aeglea Bio Therapeutics primarily active?

Aeglea Bio Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics Inc is a biotechnology company with a unique business model focused on developing therapeutic enzymes to treat rare genetic diseases and certain cancers. By leveraging its proprietary technology platform, Aeglea engineers enzymes to degrade specific amino acids in the body associated with these diseases, aiming to restore balance and improve patient outcomes. Through targeted enzyme therapy, Aeglea seeks to address significant unmet medical needs and create value for patients, healthcare providers, and shareholders.

What is the P/E ratio of Aeglea Bio Therapeutics 2024?

The Aeglea Bio Therapeutics P/E ratio is -14.03.

What is the P/S ratio of Aeglea Bio Therapeutics 2024?

The Aeglea Bio Therapeutics P/S ratio is 9.85.

What is the AlleAktien quality score of Aeglea Bio Therapeutics?

The AlleAktien quality score for Aeglea Bio Therapeutics is 1/10.

What is the revenue of Aeglea Bio Therapeutics 2024?

The expected Aeglea Bio Therapeutics revenue is 13.6 M USD.

How high is the profit of Aeglea Bio Therapeutics 2024?

The expected Aeglea Bio Therapeutics profit is -9.55 M USD.

What is the business model of Aeglea Bio Therapeutics

Aeglea Bio Therapeutics Inc. is an innovative biotechnology company based in Austin, Texas. The company was founded in 2013 and specializes in the development of therapies for rare genetic disorders. Aeglea Bio Therapeutics has a unique business model based on two pillars: the development of new drugs and collaboration with other companies and research institutions. The first pillar of Aeglea Bio Therapeutics' business model is the development of therapies for rare genetic disorders. This is achieved through the research of the role of amino acids in metabolism and their effects on specific diseases. The company utilizes innovative technologies to identify and develop new treatment approaches. This includes the production of enzymes that selectively break down certain amino acids, thereby reducing or removing disease-causing substances. The first drug developed by Aeglea Bio Therapeutics is Pegzilarginase (AEB1102), an enzyme replacement therapy for the treatment of Arginase-1 deficiency, a rare genetic disease. The second pillar of Aeglea Bio Therapeutics' business model is collaboration with other companies and research institutions. The company works with various partners in the field of research and development to accelerate the development of new drugs. Aeglea Bio Therapeutics also collaborates with biopharmaceutical companies and other organizations to bring its technologies and products to market. For example, the company has announced a partnership with Merck Sharp & Dohme Corp. (MSD) to develop combination therapy for the treatment of certain types of cancer. Aeglea Bio Therapeutics currently offers only one product, Pegzilarginase (AEB1102), which is in the clinical phase. However, the company plans to expand its portfolio by developing additional enzyme replacement therapies and treating a broader range of genetic disorders. The company has also developed a diagnostic test for quick and easy diagnosis of Arginase-1 deficiency. The business model of Aeglea Bio Therapeutics is focused on developing and commercializing innovative therapies for rare genetic disorders. The company relies on close collaboration with other partners in the field of research and development and the use of innovative technologies.

What is the Aeglea Bio Therapeutics dividend?

Aeglea Bio Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Aeglea Bio Therapeutics pay dividends?

The dividend cannot currently be calculated for Aeglea Bio Therapeutics or the company does not pay out a dividend.

What is the Aeglea Bio Therapeutics ISIN?

The ISIN of Aeglea Bio Therapeutics is US00773J1034.

What is the Aeglea Bio Therapeutics WKN?

The WKN of Aeglea Bio Therapeutics is A2AG5H.

What is the Aeglea Bio Therapeutics ticker?

The ticker of Aeglea Bio Therapeutics is AGLE.

How much dividend does Aeglea Bio Therapeutics pay?

Over the past 12 months, Aeglea Bio Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aeglea Bio Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aeglea Bio Therapeutics?

The current dividend yield of Aeglea Bio Therapeutics is .

When does Aeglea Bio Therapeutics pay dividends?

Aeglea Bio Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aeglea Bio Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aeglea Bio Therapeutics located?

Aeglea Bio Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aeglea Bio Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aeglea Bio Therapeutics from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Aeglea Bio Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Aeglea Bio Therapeutics in the year 2023?

In the year 2023, Aeglea Bio Therapeutics distributed 0 USD as dividends.

In which currency does Aeglea Bio Therapeutics pay out the dividend?

The dividends of Aeglea Bio Therapeutics are distributed in USD.

All fundamentals about Aeglea Bio Therapeutics

Our stock analysis for Aeglea Bio Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aeglea Bio Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.